HBPCF (Helix BioPharma) Total Liabilities: $4.87 Mil (As of Apr. 2026)


HBPCF Helix BioPharma Corp HBPCF
28 GF Score
Price $1.71
View Full Analysis

What is Helix BioPharma Total Liabilities?

Helix BioPharma HBPCF 28 Total Liabilities is $4.87 Mil as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100.

Helix BioPharma's Total Liabilities for the quarter that ended in Apr. 2026 was $4.87 Mil.

Helix BioPharma's quarterly Total Liabilities increased from Oct. 2025 ($2.15 Mil) to Jan. 2026 ($2.30 Mil) and increased from Jan. 2026 ($2.30 Mil) to Apr. 2026 ($4.87 Mil).

Helix BioPharma's annual Total Liabilities declined from Jul. 2023 ($1.42 Mil) to Jul. 2024 ($1.15 Mil) but then increased from Jul. 2024 ($1.15 Mil) to Jul. 2025 ($2.35 Mil).

Helix BioPharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for Helix BioPharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma Total Liabilities Chart

Helix BioPharma Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.36 2.64 1.42 1.15 2.35

Helix BioPharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.72 2.35 2.15 2.30 4.87
HBPCF
28GF Score
Helix BioPharma Corp HBPCF
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helix BioPharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Helix BioPharma's Total Liabilities for the fiscal year that ended in Jul. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.349+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.35

Total Liabilities=Total Assets (A: Jul. 2025 )-Total Equity (A: Jul. 2025 )
=13.733-11.384
=2.35

Helix BioPharma's Total Liabilities for the quarter that ended in Apr. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.866+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=4.87

Total Liabilities=Total Assets (Q: Apr. 2026 )-Total Equity (Q: Apr. 2026 )
=15.546-10.68
=4.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $4.87 Mil mean?
Helix BioPharma (HBPCF) has a Total Liabilities of $4.87 Mil as of Apr. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Helix BioPharma and its competitors.
Is Helix BioPharma's Total Liabilities too high?
Helix BioPharma's current Total Liabilities is $4.87 Mil. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's Total Liabilities compare to VRTX and REGN?
Helix BioPharma's Total Liabilities of $4.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Helix BioPharma and its competitors. Helix BioPharma's current Total Liabilities is $4.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current Total Liabilities of $4.87 Mil. The current Total Liabilities is $4.87 Mil. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current Total Liabilities is $4.87 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix BioPharma Business Description

Other Exchanges HBP0:GermanyHBP:Canada
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score

Get the complete analysis for HBPCF

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price